Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CARM
Upturn stock ratingUpturn stock rating

Carisma Therapeutics Inc. (CARM)

Upturn stock ratingUpturn stock rating
$0.5
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/18/2025: CARM (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit 0.12%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/18/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 18.80M USD
Price to earnings Ratio -
1Y Target Price 1
Price to earnings Ratio -
1Y Target Price 1
Volume (30-day avg) 28360184
Beta 2.79
52 Weeks Range 0.14 - 1.90
Updated Date 06/18/2025
52 Weeks Range 0.14 - 1.90
Updated Date 06/18/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.22

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -254.28%
Operating Margin (TTM) -250.31%

Management Effectiveness

Return on Assets (TTM) -69.64%
Return on Equity (TTM) -362.79%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 13389643
Price to Sales(TTM) 0.94
Enterprise Value 13389643
Price to Sales(TTM) 0.94
Enterprise Value to Revenue 0.67
Enterprise Value to EBITDA -0.06
Shares Outstanding 41788100
Shares Floating 31255824
Shares Outstanding 41788100
Shares Floating 31255824
Percent Insiders 27.76
Percent Institutions 31.76

Analyst Ratings

Rating 4
Target Price 1
Buy -
Strong Buy 1
Buy -
Strong Buy 1
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Carisma Therapeutics Inc.

stock logo

Company Overview

overview logo History and Background

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies. Founded in 2016, the company aims to revolutionize cancer treatment through engineered macrophages.

business area logo Core Business Areas

  • Chimeric Antigen Receptor Macrophages (CAR-M): Development of CAR-M therapies to target solid tumors. This involves genetically engineering macrophages to express CARs that specifically recognize and destroy cancer cells.

leadership logo Leadership and Structure

The company is led by Steven Kelly (CEO) and has a management team focused on research, development, and clinical operations. It operates with a structure common for biotech companies, emphasizing research and clinical trials.

Top Products and Market Share

overview logo Key Offerings

  • CT-0508 (CAR-M therapy targeting HER2-expressing solid tumors): This is their lead product candidate, currently in Phase 1 clinical trials for HER2-overexpressing solid tumors. Market share data is not yet available due to its early stage. Competitors include companies developing HER2-targeted therapies, such as Roche (Herceptin) and other CAR-T cell therapies.

Market Dynamics

industry overview logo Industry Overview

The immunotherapy market is rapidly growing, with a focus on cell therapies for cancer treatment. The industry is characterized by high innovation and competition.

Positioning

Carisma Therapeutics Inc. is positioned as a pioneer in the CAR-M field, differentiating itself from CAR-T cell therapies by leveraging macrophages.

Total Addressable Market (TAM)

The TAM for cell therapies in oncology is expected to reach billions of dollars. Carisma is positioned to capture a portion of this market with its novel macrophage-based approach.

Upturn SWOT Analysis

Strengths

  • Pioneering CAR-M technology
  • Strong scientific team
  • Early mover advantage in macrophage therapies

Weaknesses

  • Early stage clinical development
  • High cash burn rate
  • Dependence on successful clinical trial outcomes

Opportunities

  • Expanding CAR-M platform to other cancer targets
  • Partnerships with larger pharmaceutical companies
  • Positive clinical data driving market adoption

Threats

  • Competition from established CAR-T cell therapies
  • Clinical trial failures
  • Regulatory hurdles

Competitors and Market Share

competitor logo Key Competitors

  • Gilead (GILD)
  • Novartis (NVS)
  • Bristol Myers Squibb (BMY)

Competitive Landscape

Carisma Therapeutics Inc. is entering a competitive market with established players in cell therapy. Its CAR-M technology offers a novel approach, but it faces challenges in proving its efficacy and safety compared to CAR-T cell therapies.

Major Acquisitions

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by research and development progress.

Future Projections: Future growth is contingent on successful clinical trial outcomes and partnerships.

Recent Initiatives: Advancement of CT-0508 into Phase 1 clinical trials.

Summary

Carisma Therapeutics Inc. is a promising biotech company pioneering CAR-M therapy, offering a novel approach to cancer treatment. While still in early clinical stages, the company's innovative technology and strong scientific team position it for potential growth. However, it faces challenges regarding clinical trials and competition from more established therapies, highlighting the need for strong financial backing and successful clinical outcomes. The total addressable market is vast, and CARM is poised to take part.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings (when available)
  • Industry Reports
  • Analyst Reports
  • ClinicalTrials.gov

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial professional.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Carisma Therapeutics Inc.

Exchange NASDAQ
Headquaters Philadelphia, PA, United States
IPO Launch date 2014-02-06
President, CEO & Director Mr. Steven Kelly
Sector Healthcare
Industry Biotechnology
Full time employees 46
Full time employees 46

Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidate includes CT-2401, which is in preclinical trail for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.